CGTLive’s Weekly Rewind – December 2, 2022


Review top news and interview highlights from the week ending December 2, 2022.

Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. CAR-T Outcome Measures Unaffected by Socioeconomic Status and Neighborhood Opportunity

There was no significant difference in OS and CR rate for patients based on household poverty and neighborhood opportunity.

2. Arshad Khanani, MD, on Reducing Treatment Burden in Wet AMD With Gene Therapy

The director of clinical research at Sierra Eye Associates discussed unmet needs in patients with wet AMD.

3. GM1 Gangliosidosis Gene Therapy Trial Safe to Continue

Lysogene’s MPS IIIA gene therapy program recently failed its primary endpoint in the phase 2/3 AAVANCE trial.

4. Hemgenix Approval May Pave Way for Val-Rox in Hemophilia A

The FDA has decided not to hold an advisory committee meeting for Roctavian after all.

5. Maria Escolar, MD, on Addressing Unmet Needs in Krabbe Disease With Gene Therapy

The chief medical officer of Forge Biologics discussed clinical data presented at ESGCT.

Recent Videos
David Dimmock, MBBS, on AI-Guided ASO Development for Ultra-Rare Diseases
Manali Kamdar, MD, on The Importance of Bringing Liso-Cel to Earlier Lines of Lymphoma Treatment
Lisa Nieland on Slowing Tumor Growth in Glioblastoma With Novel AAV Therapy
Manali Kamdar, MD, on Acclimating to Routine CAR T Practice in the Field
Leigh Ramos-Platt, MD, on Looking Forward to Gene Therapy’s Growth
Manali Kamdar, MD, on Evaluating Liso-Cel in Mantle Cell Lymphoma by Lines of Therapy, Prior BTKi
Mark Walters, MD
Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment
Omid Hamid, MD, on Assessing TIL Combination Therapies, Expanding Past Melanoma
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
© 2024 MJH Life Sciences

All rights reserved.